Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
psilocybin + midazolam
- Development stage
- Phase 1
- Lead developer
- University of Wisconsin–Madison
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of psilocybin and midazolam being investigated to understand the role of conscious experience and memory in the therapeutic effects of psychedelics. Psilocybin produces psychedelic effects while midazolam induces amnesia while allowing the conscious experience to occur. This combination enables researchers to determine whether memory of the psychedelic experience is necessary for psilocybin's therapeutic effects, particularly its antidepressant properties.
- Other names
- Psilocybin and Midazolam
02
Targets
HTR2A (Serotonin receptor 5-HT2A)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on psilocybin + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on psilocybin + midazolam.